Trinity Biotech (TRIB) Amortization - Deferred Charges (2015 - 2024)

Trinity Biotech has disclosed Amortization - Deferred Charges across 10 years of filings, most recently posting -$4.3 million for Q4 2024.

• Amortization - Deferred Charges for Q4 2024 came in at -$4.3 million, down 148.2% year-over-year; the trailing twelve-month figure through Dec 2024 was -$16.6 million (down 14.03% YoY), and the FY2024 annual result was -$9.6 million, up 3.21% from the prior year.
• Amortization - Deferred Charges came in at -$4.3 million for Q4 2024 at Trinity Biotech, down from -$1.7 million in the prior quarter.
• In the past five years, Amortization - Deferred Charges ranged from a high of -$346000.0 in Q2 2021 to a low of -$8.3 million in Q2 2022.
• The 5-year median for Amortization - Deferred Charges is -$1.2 million (2020), against an average of -$2.3 million.
• Across the five-year window, Amortization - Deferred Charges jumped 71.62% in 2021 and plunged 2298.84% in 2022, its largest moves.
• Trinity Biotech's Amortization - Deferred Charges stood at -$1.2 million in 2020, then plunged by 144.36% to -$3.0 million in 2021, then grew by 24.04% to -$2.3 million in 2022, then increased by 24.03% to -$1.7 million in 2023, then sank by 148.2% to -$4.3 million in 2024.
• The last three Amortization - Deferred Charges figures came in at -$4.3 million (Q4 2024), -$1.7 million (Q4 2023), and -$2.3 million (Q4 2022), per Business Quant data.